The information highlighted (if any) are the most recent updates for this brand.
This drug is contraindicated in patients with hypersensitivity to Desvenlafaxine succinate, venlafaxine hydrochloride, or any ingredients in the formulation; in patient with concurrent or recent (i.e., within 2 weeks) therapy with a monoamine oxidase (MAO) inhibitor. In addition, at least 2 weeks should elapse between discontinuance of a MAO-inhibitor and initiation of Desvenlafaxine and at least 7 days should elapse between discontinuance of Desvenlafaxine and initiation of MAO inhibitor therapy.